• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
TechCloud Computing

Medical researchers use the cloud to do what they couldn’t before

Barb Darrow
By
Barb Darrow
Barb Darrow
Down Arrow Button Icon
Barb Darrow
By
Barb Darrow
Barb Darrow
Down Arrow Button Icon
June 19, 2015, 10:55 AM ET
<h1>DNA Rx</h1>


In 2003, a team of researchers working for the Department of Energy and the National Institutes of Health completed a 13-year long effort called the Human Genome Project. The goal of the project was, among other things, to identify and map every gene in human DNA. For a while, the scientific community has been looking at the data and wondering, "So, what's next?" 


One answer is targeted therapy, medical treatments that do not only address symptoms, but also respond to a patient's genetic makeup. 


The past couple of years have yielded breakthroughs in this field. In 2011, a team of scientists at the University of Pennsylvania effectively treated leukemia patients by engineering their own white blood cells to fight the disease. Also in 2011, researchers in Britain achieved promising results in treating the genetic disease hemophilia B by injecting patients with a re-engineered version of the gene. 2012 brought even more advancements, using targeted therapy to treat inherited blindness.


"Talk about transforming an industry," says George Day, co-director of the Mack Center at Wharton. "Big Pharma has always been pill-based," he says, meaning patients need daily dosage, whereas "gene therapy is one and done.


"I think finally after 20 years, the promise of gene therapy is starting to be realized."
<h1>DNA Rx</h1> In 2003, a team of researchers working for the Department of Energy and the National Institutes of Health completed a 13-year long effort called the Human Genome Project. The goal of the project was, among other things, to identify and map every gene in human DNA. For a while, the scientific community has been looking at the data and wondering, "So, what's next?" One answer is targeted therapy, medical treatments that do not only address symptoms, but also respond to a patient's genetic makeup. The past couple of years have yielded breakthroughs in this field. In 2011, a team of scientists at the University of Pennsylvania effectively treated leukemia patients by engineering their own white blood cells to fight the disease. Also in 2011, researchers in Britain achieved promising results in treating the genetic disease hemophilia B by injecting patients with a re-engineered version of the gene. 2012 brought even more advancements, using targeted therapy to treat inherited blindness. "Talk about transforming an industry," says George Day, co-director of the Mack Center at Wharton. "Big Pharma has always been pill-based," he says, meaning patients need daily dosage, whereas "gene therapy is one and done. "I think finally after 20 years, the promise of gene therapy is starting to be realized." Illustration: Alfred Pasieka/Getty Images

Cloud computing—and the ability it gives researchers to quickly add and shut down resources as needed—means that they can do massive number crunching that researchers could not have dreamed of in the past.

That’s probably one reason that Matthew Trunnell will upgrade legacy software at Seattle’s Fred Hutchinson Cancer Research Center to rely more on the cloud, according to the the Wall Street Journal. Trunnell, who is now CIO of the Broad Institute in Cambridge, Mass., will join Hutchinson as CIO in a few months.

Trunnell cited cloud computing as a way to advance “precision medicine” which is the practice of sequencing the genome of tumors and applying big data analytics to improve care.

The real key here is that the advent of huge web-scale computational capability—applying tens of thousands of computer nodes to a problem— brings supercomputer-like power to bear on very tough problems. In the past researchers who needed that sort of heavy-lifting had to sign up for time at one of the nation’s supercomputing centers. And then they waited, for weeks if not months. That’s clearly not optimal in for a specialty that wants to work fast and iteratively on tough problems.

Cycle Computing, which makes software that manages research applications so they can run across clouds, sees a lot of these applications moving to the cloud up close and personal.

“Every day, we witness engineers and scientists benefit from limitless access to compute, thanks to cloud,” said Cycle CEO Jason Stowe. “Steve Litster’s team at Novartis ran 40 years of cancer drug simulation in 8 hours, for thousands of dollars instead of millions. The critical value of cloud [computing] is not saving dollars, it is enabling researchers to do things they couldn’t do before.”

Litster is global lead for high-performance and scientific computing for the Novartis (NVSEF) Institutes for Biomedical Research

There are other examples of cloud computing being put to use in big projects, one being Autism Speaks’ use of Google(GOOG) Cloud for its genomic research.

Trunnell said the Broad Institute is testing Amazon(AMZN) and Google clouds now, and he plans to talk to those companies, as well as Microsoft(MSFT), when he starts his new job.

Subscribe to Data Sheet, Fortune’s daily newsletter on the business of technology.

About the Author
Barb Darrow
By Barb Darrow
See full bioRight Arrow Button Icon

Latest in Tech

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Latest in Tech

gen z
Commentarydisruption
AI won’t kill your job — it will kill the path to your first one
By Jeffrey Sonnenfeld, Stephen Henriques, Johan Griesel, Andrew Alam-Nist and Peter YuApril 29, 2026
10 minutes ago
Christina Cacioppo poses while sitting down in a suit jacket
NewslettersTerm Sheet
Exclusive: Vanta hits $300 million ARR as ‘shadow AI’ explodes across corporate America
By Lily Mae LazarusApril 29, 2026
2 hours ago
Tariff-proof pay: How boardrooms quietly made sure Trump’s trade war stopped at the CEO’s door
Big TechMarkets
Tariff-proof pay: How boardrooms quietly made sure Trump’s trade war stopped at the CEO’s door
By Jim EdwardsApril 29, 2026
3 hours ago
From encyclopedias to AI: How knowledge is changing the way we work
AIProductivity
From encyclopedias to AI: How knowledge is changing the way we work
By Bruce BroussardApril 29, 2026
3 hours ago
Elon Musk in Oakland, California on April 28, 2026. (Photo: Jessica Christian/San Francisco Chronicle/Getty Images)
NewslettersFortune Tech
Judge to Altman and Musk: Keep a lid on it
By Andrew NuscaApril 29, 2026
3 hours ago
AI
AIProductivity
The uncomfortable truth about AI and the American worker
By Nick LichtenbergApril 29, 2026
5 hours ago

Most Popular

Apple cofounder Ronald Wayne—whose stake would be worth up to $400 billion had he not sold it in 1976—says that at 91, he has no regrets
Success
Apple cofounder Ronald Wayne—whose stake would be worth up to $400 billion had he not sold it in 1976—says that at 91, he has no regrets
By Preston ForeApril 27, 2026
2 days ago
‘The cost of compute is far beyond the costs of the employees’: Nvidia executive says right now AI is more expensive than paying human workers
AI
‘The cost of compute is far beyond the costs of the employees’: Nvidia executive says right now AI is more expensive than paying human workers
By Sasha RogelbergApril 28, 2026
1 day ago
The U.S. military may have already used up half of its most expensive missiles, and it could take up to 4 years to rebuild its stockpiles
Politics
The U.S. military may have already used up half of its most expensive missiles, and it could take up to 4 years to rebuild its stockpiles
By Sasha RogelbergApril 24, 2026
5 days ago
Current price of gold as of April 28, 2026
Personal Finance
Current price of gold as of April 28, 2026
By Danny BakstApril 28, 2026
23 hours ago
Current price of silver as of Tuesday, April 28, 2026
Personal Finance
Current price of silver as of Tuesday, April 28, 2026
By Joseph HostetlerApril 28, 2026
23 hours ago
OPEC shocker as UAE leaves oil cartel days after negotiating swap lines with Scott Bessent’s Treasury
Energy
OPEC shocker as UAE leaves oil cartel days after negotiating swap lines with Scott Bessent’s Treasury
By Nick LichtenbergApril 28, 2026
22 hours ago

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.